143 related articles for article (PubMed ID: 2555048)
1. Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine(cyclobutanedicarboxylato)platinum (II).
Schmalbach TK; Borch RF
Cancer Res; 1989 Dec; 49(23):6629-33. PubMed ID: 2555048
[TBL] [Abstract][Full Text] [Related]
2. Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum(II) or diammine-(1,1-cyclobutanedicarboxylato)platinum(II).
Gringeri A; Keng PC; Borch RF
Cancer Res; 1988 Oct; 48(20):5708-12. PubMed ID: 2844391
[TBL] [Abstract][Full Text] [Related]
3. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
4. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents.
Montine TJ; Borch RF
Cancer Res; 1988 Nov; 48(21):6017-24. PubMed ID: 2458831
[TBL] [Abstract][Full Text] [Related]
5. Myeloprotective effect of diethyldithiocarbamate treatment following 1,3-bis(2-chloroethyl)-1-nitrosourea, adriamycin, or mitomycin C in mice.
Schmalbach TK; Borch RF
Cancer Res; 1989 May; 49(10):2574-7. PubMed ID: 2540902
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of diethyldithiocarbamate modulation of murine bone marrow toxicity.
Schmalbach TK; Borch RF
Cancer Res; 1990 Oct; 50(19):6218-21. PubMed ID: 2169339
[TBL] [Abstract][Full Text] [Related]
7. Modification of the bone marrow toxicity of cis-diamminedichloroplatinum(II) in mice by diethyldithiocarbamate.
Evans RG; Wheatley C; Engel C; Nielsen J; Ciborowski LJ
Cancer Res; 1984 Sep; 44(9):3686-90. PubMed ID: 6331656
[TBL] [Abstract][Full Text] [Related]
8. Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition.
Bodenner DL; Dedon PC; Keng PC; Borch RF
Cancer Res; 1986 Jun; 46(6):2745-50. PubMed ID: 2870800
[TBL] [Abstract][Full Text] [Related]
9. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.
Konstantinov S; Topashka-Ancheva M; Karaivanova M; Zoneva G; Galova I
Neoplasma; 1994; 41(5):253-8. PubMed ID: 7854494
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.
Micetich KC; Barnes D; Erickson LC
Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
Prajda N; Kralovánszky J; Gal F; Kiss F; Kerpel-Fronius S
In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II)-induced DNA interstand cross-link removal and potentiation of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II) cytotoxicity by hydroxyurea and 1-beta-D-arabinofuranosylcytosine.
Swinnen LJ; Ellis NK; Erickson LC
Cancer Res; 1991 Apr; 51(8):1984-9. PubMed ID: 2009517
[TBL] [Abstract][Full Text] [Related]
13. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.
Terheggen PM; Floot BG; Scherer E; Begg AC; Fichtinger-Schepman AM; den Engelse L
Cancer Res; 1987 Dec; 47(24 Pt 1):6719-25. PubMed ID: 3315190
[TBL] [Abstract][Full Text] [Related]
15. Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice.
Panasci LC; Green D; Schein PS
J Clin Invest; 1979 Oct; 64(4):1103-11. PubMed ID: 158033
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
17. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
Ohno S; Strebel FR; Stephens LC; Siddik ZH; Makino M; Klostergaard J; Tomasovic SP; Khokhar AR; Bull JM
Cancer Res; 1992 Aug; 52(15):4096-101. PubMed ID: 1638521
[TBL] [Abstract][Full Text] [Related]
18. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities.
Damia G; Komschlies KL; Futami H; Back T; Gruys ME; Longo DL; Keller JR; Ruscetti FW; Wiltrout RH
Cancer Res; 1992 Aug; 52(15):4082-9. PubMed ID: 1638519
[TBL] [Abstract][Full Text] [Related]
19. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the ability to purge tumor from murine bone marrow using clonogenic assays.
Jones RJ; Colvin OM; Sensenbrenner LL
Cancer Res; 1988 Jun; 48(12):3394-7. PubMed ID: 3285994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
